The Technical Analyst
Alkermes Plc [ALKS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Alkermes Plc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.92% $24.07
America/New_York / 22 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4 021.52 mill |
| EPS: | 3.06 |
| P/E: | 7.87 |
| Earnings Date: | Feb 15, 2024 |
| SharesOutstanding: | 167.08 mill |
| Avg Daily Volume: | 1.990 mill |
| RATING 2024-04-22 |
|---|
| S- |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Buy | |
| P/E: | Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 7.87 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 1.34x |
| Company: PE 7.87 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$17.21 (-28.49%) $-6.86 |
| Date: 2024-04-22 |
| Expected Trading Range (DAY) |
|---|
|
$ 23.33 - 24.82 ( +/- 3.10%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-11 | Lurker Nancy | Buy | 22 103 | Non Qualified Stock Option (Right to Buy) |
| 2024-04-11 | Lurker Nancy | Buy | 11 255 | Restricted Stock Unit Award |
| 2024-04-11 | Lurker Nancy | Buy | 4 833 | Non Qualified Stock Option (Right to Buy) |
| 2024-04-11 | Lurker Nancy | Buy | 2 323 | Restricted Stock Unit Award |
| 2024-03-18 | Nichols Christian Todd | Sell | 10 417 | Ordinary Shares |
| INSIDER POWER |
|---|
| 75.16 |
| Last 99 transactions |
| Buy: 1 207 179 | Sell: 170 568 |
Forecast:
16:00 - $24.07
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $24.07
Forecast 2: 16:00 - $24.07
Forecast 3: 16:00 - $24.07
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $24.07 (0.92% ) |
| Volume | 1.543 mill |
| Avg. Vol. | 1.990 mill |
| % of Avg. Vol | 77.54 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ALKS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $26.69 | N/A | Active |
|---|
ALKS
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Latest Press Releases
2024-04-17 16:00:00 - Press Release
Alkermes To Report First Quarter Financial Results On May 1, 2024
Dublin , april 17, 2024 /prnewswire/ -- alkermes plc (nasdaq: alks) will host a conference call and webcast presentation at 8:00 a.m. et (1:00 p.m.
2024-04-09 07:00:00 - Press Release
Alkermes Announces Positive Topline Results From Phase 1b Study Of Alks 2680 Demonstrating Improved Wakefulness In Patients With Narcolepsy Type 2 And Idiopathic Hypersomnia
— orexin 2 receptor agonist alks 2680 demonstrated clinically meaningful and statistically significant improvements from baseline in mean sleep latency compared to placebo at all doses tested in both narcolepsy type 2 and idiopathic hypersomnia — — alks 2680 was generally well tolerated at all doses tested — — dose-dependent effects and pharmacodynamic profile support advancement into planned phase 2 study — dublin , april 9, 2024 /prnewswire/ -- alkermes plc (nasdaq: alks) today announced positive topline results from the narcolepsy type 2 (nt2) and idiopathic hypersomnia (ih) cohorts of a phase 1b, proof-of-concept study evaluating alks 2680, the company's novel, investigational, oral orexin 2 receptor (ox2r) agonist in development as a once-daily treatment for narcolepsy...
2024-04-08 07:00:00 - Press Release
Alkermes Presents Analyses From Long-term Safety Study Of Lybalvi® (olanzapine And Samidorphan) At 2024 Congress Of The Schizophrenia International Research Society
Dublin , april 8, 2024 /prnewswire/ -- alkermes plc (nasdaq: alks) today announced the oral presentation of clinical data at the 2024 congress of the schizophrenia international research society (sirs), which took place april 3-7, 2024 in florence, italy. analyses were presented from a phase 3, open-label extension study assessing the long-term safety, tolerability and durability of treatment effect of lybalvi® (olanzapine and samidorphan) in patients who received up to four years of treatment.
2024-03-07 07:00:00 - Press Release
Alkermes Announces Appointment Of Nancy S. Lurker To Board Of Directors
Dublin , march 7, 2024 /prnewswire/ -- alkermes plc (nasdaq: alks) today announced the appointment of a new independent director, nancy s. lurker, to the company's board of directors (the board).
2024-02-15 07:00:00 - Press Release
Alkermes Plc Reports Financial Results For The Fourth Quarter And Year Ended Dec. 31, 2023 And Provides Financial Expectations For 2024
— total revenues of $1.66 billion in 2023; net sales of proprietary products increased approximately 18% year-over-year — — gaap net income of $356 million and diluted gaap earnings per share of $2.10 for 2023 — — company expects to generate 30% ebitda margin in 2024 — dublin , feb. 15, 2024 /prnewswire/ -- alkermes plc (nasdaq: alks) today reported financial results for the quarter and year ended dec. 31, 2023 and provided financial expectations for 2024. "we entered 2024 as a pure-play neuroscience company and are well positioned to deliver on our strategic priorities to drive growth of our proprietary commercial products, advance the clinical development of alks 2680 for the treatment of narcolepsy, and generate significant cash flow," said richard pops, chief executive officer of alkermes.
Latest News
2024-04-22 15:16:21 - Zacks Investment Research
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and combat stiff competition in 2024.
2024-04-11 11:16:05 - Zacks Investment Research
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
Alkermes (ALKS) reports positive top-line data from a phase Ib, proof-of-concept study investigating ALKS 2680 for the treatment of narcolepsy.
2024-04-09 16:29:10 - Seeking Alpha
Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data
Alkermes reports positive Phase 1 results for ALKS-2680 in narcolepsy and idiopathic hypersomnia, with significant efficacy and manageable side effects. The company plans to proceed with a Phase 2 study for ALKS-2680 in Narcolepsy Type 2 later this year. Q4 earnings show robust revenue growth, led by Lybalvi, which significantly outpaced other products with 61% year-over-year growth.
2024-04-02 13:16:08 - Zacks Investment Research
Why Alkermes (ALKS) is Poised to Beat Earnings Estimates Again
Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
2024-03-20 09:50:27 - Zacks Investment Research
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
2024-03-13 13:46:06 - Zacks Investment Research
3 Reasons Why Alkermes (ALKS) Is a Great Growth Stock
Alkermes (ALKS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
2024-03-12 10:50:17 - Zacks Investment Research
Here's Why Alkermes (ALKS) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
2024-03-08 10:51:15 - Zacks Investment Research
Here's Why Alkermes (ALKS) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
2024-03-07 19:16:10 - Zacks Investment Research
Why Alkermes (ALKS) Outpaced the Stock Market Today
Alkermes (ALKS) concluded the recent trading session at $29.45, signifying a +1.76% move from its prior day's close.
2024-02-29 19:16:11 - Zacks Investment Research
Alkermes (ALKS) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Alkermes (ALKS) stood at $29.69, denoting a -0.37% change from the preceding trading day.